0001396814-24-000088.txt : 20240703
0001396814-24-000088.hdr.sgml : 20240703
20240703185222
ACCESSION NUMBER: 0001396814-24-000088
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240628
FILED AS OF DATE: 20240703
DATE AS OF CHANGE: 20240703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SLONIN JONATHAN
CENTRAL INDEX KEY: 0001875723
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35060
FILM NUMBER: 241101262
MAIL ADDRESS:
STREET 1: C/O PACIRA BIOSCIENCES, INC.
STREET 2: 5401 WEST KENNEDY BOULEVARD, SUITE 890
CITY: TAMPA
STATE: FL
ZIP: 33609
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pacira BioSciences, Inc.
CENTRAL INDEX KEY: 0001396814
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 510619477
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5401 WEST KENNEDY BOULEVARD
STREET 2: SUITE 890
CITY: TAMPA
STATE: FL
ZIP: 33609
BUSINESS PHONE: 813-553-6680
MAIL ADDRESS:
STREET 1: 5401 WEST KENNEDY BOULEVARD
STREET 2: SUITE 890
CITY: TAMPA
STATE: FL
ZIP: 33609
FORMER COMPANY:
FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20101029
FORMER COMPANY:
FORMER CONFORMED NAME: PACIRA INC
DATE OF NAME CHANGE: 20080318
FORMER COMPANY:
FORMER CONFORMED NAME: Blue Acquisition Corp
DATE OF NAME CHANGE: 20070418
4
1
wk-form4_1720047136.xml
FORM 4
X0508
4
2024-06-28
0
0001396814
Pacira BioSciences, Inc.
PCRX
0001875723
SLONIN JONATHAN
C/O PACIRA BIOSCIENCES, INC.
5401 WEST KENNEDY BOULEVARD, SUITE 890
TAMPA
FL
33609
0
1
0
0
Chief Medical Officer
1
Common Stock
2024-06-28
5
A
0
E
437.271
24.319
A
99306.746
D
Common Stock
2024-07-01
4
F
0
914
28.46
D
98392.746
D
Common Stock
2024-07-02
4
S
0
2836
28.25
D
95556.746
D
Represents shares of common stock acquired under the issuer's employee stock purchase plan in June 2024.
Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
/s/ Kristen Williams, Attorney-in-Fact
2024-07-03